Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.53
-1.5%
$0.46
$0.37
$1.62
$2.59M0.45378,063 shs1,224 shs
Inspira Technologies Oxy B.H.N. Ltd. stock logo
IINN
Inspira Technologies Oxy B.H.N.
$1.90
+5.6%
$1.72
$0.76
$2.49
$22.72M2.23285,335 shs61,301 shs
Nephros, Inc. stock logo
NEPH
Nephros
$2.09
-0.5%
$2.60
$1.13
$4.04
$22.03M1.3113,450 shs25,848 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$1.61
-3.0%
$1.86
$0.97
$5.09
$6.89M0.5931,568 shs2,201 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynatronics Co. stock logo
DYNT
Dynatronics
+1.13%+45.01%+17.47%+9.80%-62.90%
Inspira Technologies Oxy B.H.N. Ltd. stock logo
IINN
Inspira Technologies Oxy B.H.N.
+5.56%-1.55%+9.20%+108.36%+62.39%
Nephros, Inc. stock logo
NEPH
Nephros
-0.48%+5.03%-11.81%-40.79%+48.23%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
+1.84%-4.60%-11.23%-23.85%-58.08%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dynatronics Co. stock logo
DYNT
Dynatronics
1.9094 of 5 stars
3.05.00.00.02.50.00.6
Inspira Technologies Oxy B.H.N. Ltd. stock logo
IINN
Inspira Technologies Oxy B.H.N.
N/AN/AN/AN/AN/AN/AN/AN/A
Nephros, Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
1.1614 of 5 stars
3.53.00.00.01.90.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dynatronics Co. stock logo
DYNT
Dynatronics
2.00
Hold$3.80616.98% Upside
Inspira Technologies Oxy B.H.N. Ltd. stock logo
IINN
Inspira Technologies Oxy B.H.N.
N/AN/AN/AN/A
Nephros, Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.00
Buy$10.00521.12% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dynatronics Co. stock logo
DYNT
Dynatronics
$40.61M0.06N/AN/A$2.19 per share0.24
Inspira Technologies Oxy B.H.N. Ltd. stock logo
IINN
Inspira Technologies Oxy B.H.N.
N/AN/AN/AN/A$0.45 per shareN/A
Nephros, Inc. stock logo
NEPH
Nephros
$14.24M1.55N/AN/A$0.80 per share2.61
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$4.91M1.40N/AN/A($0.30) per share-5.37

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dynatronics Co. stock logo
DYNT
Dynatronics
-$4.97M-$1.38N/AN/A-14.13%-54.88%-16.14%5/9/2024 (Estimated)
Inspira Technologies Oxy B.H.N. Ltd. stock logo
IINN
Inspira Technologies Oxy B.H.N.
-$11.29MN/A0.00N/AN/A-158.18%-108.21%6/24/2024 (Estimated)
Nephros, Inc. stock logo
NEPH
Nephros
-$1.58M-$0.15N/AN/A-11.06%-18.25%-14.29%5/8/2024 (Estimated)
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$13.32M-$33.76N/AN/AN/A-271.04%-805.57%-97.73%4/25/2024 (Estimated)

Latest PSTV, IINN, DYNT, and NEPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/7/2024Q4 2023
Nephros, Inc. stock logo
NEPH
Nephros
N/A-$0.06-$0.06-$0.06N/A$3.25 million    
3/5/2024Q4 2023
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.78-$0.70+$0.08-$0.70$1.26 million$1.31 million
2/7/2024Q2 2024
Dynatronics Co. stock logo
DYNT
Dynatronics
N/A-$0.27-$0.27-$0.27N/A$8.15 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
Inspira Technologies Oxy B.H.N. Ltd. stock logo
IINN
Inspira Technologies Oxy B.H.N.
N/AN/AN/AN/AN/A
Nephros, Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dynatronics Co. stock logo
DYNT
Dynatronics
0.21
1.41
0.67
Inspira Technologies Oxy B.H.N. Ltd. stock logo
IINN
Inspira Technologies Oxy B.H.N.
0.10
2.61
2.61
Nephros, Inc. stock logo
NEPH
Nephros
N/A
3.98
2.81
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
0.92
0.92

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
Inspira Technologies Oxy B.H.N. Ltd. stock logo
IINN
Inspira Technologies Oxy B.H.N.
12.72%
Nephros, Inc. stock logo
NEPH
Nephros
41.10%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%

Insider Ownership

CompanyInsider Ownership
Dynatronics Co. stock logo
DYNT
Dynatronics
9.10%
Inspira Technologies Oxy B.H.N. Ltd. stock logo
IINN
Inspira Technologies Oxy B.H.N.
29.40%
Nephros, Inc. stock logo
NEPH
Nephros
4.10%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.32%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Dynatronics Co. stock logo
DYNT
Dynatronics
1544.88 million4.44 millionNot Optionable
Inspira Technologies Oxy B.H.N. Ltd. stock logo
IINN
Inspira Technologies Oxy B.H.N.
3212.62 million8.91 millionNot Optionable
Nephros, Inc. stock logo
NEPH
Nephros
3110.54 million10.11 millionNot Optionable
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
204.28 million4.18 millionNot Optionable

PSTV, IINN, DYNT, and NEPH Headlines

SourceHeadline
Plus Therapeutics (NASDAQ:PSTV) Trading Up 1.8%Plus Therapeutics (NASDAQ:PSTV) Trading Up 1.8%
americanbankingnews.com - April 23 at 1:48 AM
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of DefenseMicro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
finance.yahoo.com - April 22 at 10:35 AM
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of DefensePlus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
globenewswire.com - April 22 at 7:00 AM
Plus Therapeutics, Inc. (PSTV)Plus Therapeutics, Inc. (PSTV)
finance.yahoo.com - April 19 at 12:11 AM
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management TeamNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
finance.yahoo.com - April 9 at 7:57 AM
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.
globenewswire.com - April 9 at 7:00 AM
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual ConferencePlus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
finance.yahoo.com - March 27 at 10:29 AM
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell DiagnosticPlus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
finance.yahoo.com - March 25 at 8:51 AM
Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry TailwindsBuy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds
markets.businessinsider.com - March 23 at 7:41 AM
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal MetastasesPlus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
finance.yahoo.com - March 11 at 9:16 AM
Plus Therapeutics Full Year 2023 Earnings: Beats ExpectationsPlus Therapeutics Full Year 2023 Earnings: Beats Expectations
finance.yahoo.com - March 7 at 10:46 AM
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call TranscriptPlus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 7 at 10:46 AM
Q4 2023 Plus Therapeutics Inc Earnings CallQ4 2023 Plus Therapeutics Inc Earnings Call
finance.yahoo.com - March 6 at 6:24 PM
PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023
investorplace.com - March 5 at 10:33 PM
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue EstimatesPlus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
zacks.com - March 5 at 6:36 PM
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsPlus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
globenewswire.com - March 5 at 4:05 PM
IMUNON stock rallies 19% on early results for COVID-19 vaccineIMUNON stock rallies 19% on early results for COVID-19 vaccine
msn.com - February 29 at 1:33 PM
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
finance.yahoo.com - February 27 at 8:49 AM
Plus Therapeutics Inc PSTVPlus Therapeutics Inc PSTV
morningstar.com - February 21 at 6:55 PM
Plus Therapeutics Inc [PSTV] Stock sold by Insider HEDRICK MARC H for $4053.0Plus Therapeutics Inc [PSTV] Stock sold by Insider HEDRICK MARC H for $4053.0
knoxdaily.com - January 1 at 10:51 PM
Plus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024Plus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024
finanznachrichten.de - December 18 at 1:46 PM
Plus Updates Financial and Cash Guidance for 2024Plus Updates Financial and Cash Guidance for 2024
finance.yahoo.com - December 18 at 8:46 AM
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker AnalysesPlus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
finance.yahoo.com - December 12 at 10:20 AM
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)
markets.businessinsider.com - November 29 at 8:56 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Dynatronics logo

Dynatronics

NASDAQ:DYNT
Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.
Inspira Technologies Oxy B.H.N. logo

Inspira Technologies Oxy B.H.N.

NASDAQ:IINN
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.
Nephros logo

Nephros

NASDAQ:NEPH
Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Plus Therapeutics logo

Plus Therapeutics

NASDAQ:PSTV
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.